137 related articles for article (PubMed ID: 22739156)
21. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35.
Tao Q; Chen T; Tao L; Wang H; Pan Y; Xiong S; Zhai Z
J Immunother; 2013; 36(9):462-7. PubMed ID: 24145357
[TBL] [Abstract][Full Text] [Related]
22. [Biological characteristics of PHA-induced CIK cells and its killing activity to K562 cells].
Huang MZ; Bai J; Li FS; Liu YL; Li MM; Li YH; Zhang LS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):64-8. PubMed ID: 24598653
[TBL] [Abstract][Full Text] [Related]
23. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
24. [Specific immune cell therapy against ovarian cancer in vivo and in vitro].
Chang XH; Cheng HY; Cheng YX; Ye X; Guo HF; Fu TY; Zhang L; Zhang G; Cui H
Ai Zheng; 2008 Dec; 27(12):1244-50. PubMed ID: 19079987
[TBL] [Abstract][Full Text] [Related]
25. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol.
Rutella S; Iudicone P; Bonanno G; Fioravanti D; Procoli A; Lavorino C; Foddai ML; Lorusso D; Martinelli E; Vacca M; Ipsevich F; Nuti M; Scambia G; Pierelli L
Cytotherapy; 2012 Aug; 14(7):841-50. PubMed ID: 22563888
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract][Full Text] [Related]
28. Influence of dendritic cells on biological activity of the homologous CIK cells and its anti-leukemia effect in vitro.
Wei XC; Zhai XH; Han XR; Yang DD; Wang QS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):946-51. PubMed ID: 20723306
[TBL] [Abstract][Full Text] [Related]
29. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
[TBL] [Abstract][Full Text] [Related]
30. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
31. [The efficacy of chemotherapy in combination with auto-cytokine-induced killer cells in acute leukemia].
Jiang H; Liu KY; Tong CR; Jiang B; Lu DP
Zhonghua Nei Ke Za Zhi; 2005 Mar; 44(3):198-201. PubMed ID: 15840260
[TBL] [Abstract][Full Text] [Related]
32. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Wu C; Jiang J; Shi L; Xu N
Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
[TBL] [Abstract][Full Text] [Related]
35. [Effect of lingdankang composite combined dendritic cell-cytokine induced killer cells in treating leukemia].
Liu QC; Wu WH; Li GR
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Apr; 29(4):347-50. PubMed ID: 19526763
[TBL] [Abstract][Full Text] [Related]
36. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
37. Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells.
Zanon C; Stocchero M; Albiero E; Castegnaro S; Chieregato K; Madeo D; Rodeghiero F; Astori G
Cytometry B Clin Cytom; 2014 Jul; 86(4):257-62. PubMed ID: 24002818
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells.
Lin G; Wang J; Lao X; Wang J; Li L; Li S; Zhang J; Dong Y; Chang AE; Li Q; Li S
J Immunother; 2012 May; 35(4):337-43. PubMed ID: 22495391
[TBL] [Abstract][Full Text] [Related]
39. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells.
Li Y; Schmidt-Wolf IG; Wu YF; Huang SL; Wei J; Fang J; Huang K; Zhou DH
Anticancer Res; 2010 Sep; 30(9):3493-9. PubMed ID: 20944128
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood.
Zhang Z; Zhao X; Zhang T; Wang L; Yang L; Huang L; Li F; Liu J; Yue D; Wang F; Li J; Guan F; Xu Y; Zhang B; Zhang Y
Cytotherapy; 2015 Jan; 17(1):86-97. PubMed ID: 25457278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
